Key Highlights

  • Medpace (NASDAQ:MEDP) reported net new business awards of USD 873.4 million on Wednesday, October 21, 2026, up 10.6%, or about 1.22 times quarterly revenue of USD 716.0 million on simple arithmetic.
  • Backlog rose 5.6% to USD 3.17 billion at September 30, 2026, and the release puts the quarterly backlog conversion rate, the share of backlog turned into revenue, at 23.8%.
  • Diluted EPS of USD 4.84, up from USD 3.86, beat the consensus estimate of USD 4.46, as EBITDA rose 16.0% to USD 172.1 million at a 24.0% margin.
  • The board ended the prior buyback programme, which had USD 527.0 million left, and approved up to USD 1.0 billion of repurchases through December 31, 2028, after no buybacks in the quarter.

Awards, Backlog and a Fresh Buyback

Medpace (NASDAQ:MEDP), the Cincinnati-based contract research organisation that runs clinical trials for drug developers, reported third-quarter results after the close on Wednesday, October 21, 2026. Revenue rose 8.5% to USD 716.0 million. Net new business awards, the value of contracts signed minus cancellations, rose 10.6% to USD 873.4 million. Backlog reached USD 3,167.2 million, up 5.6% from USD 3,000.6 million. EBITDA rose 16.0% to USD 172.1 million, and the margin widened to 24.0% from 22.5%. Net income was USD 137.5 million, or USD 4.84 per diluted share, against the consensus estimate of USD 4.46. Cash stood at USD 705.3 million after quarterly operating cash flow of USD 216.6 million. The board also replaced its buyback authorisation with a larger one.

How Awards Turn Into Future Revenue

For Medpace (NASDAQ:MEDP), awards matter because they refill backlog, the pool of contracted work not yet performed. Book-to-bill, awards divided by revenue, shows whether that pool is growing, and a ratio above 1.0 means more work was signed than delivered. At about 1.22, calculated from published figures, the quarter added roughly USD 157 million more in awards than it recognised as revenue. Backlog growth of 5.6% year on year trails awards growth because each quarter's revenue draws down existing contracts, at a conversion rate the release puts at 23.8%. That rate matters as much as bookings: faster conversion lifts near-term revenue but thins the cushion. Full-year revenue guidance of USD 2.835 billion to USD 2.855 billion implies growth of 12.0% to 12.8%.

Risks and What to Watch

The first risk for Medpace (NASDAQ:MEDP) is cancellations, because net awards already subtract them and a rise would cut both awards and backlog quickly. The second is client funding: the company works largely for smaller biotechnology sponsors, whose budgets depend on capital markets, and the federal funds range stands at 3.75% to 4.00% after the September 16 increase. The third is capital allocation, since a USD 1.0 billion authorisation exceeds cash of USD 705.3 million, so full use would draw on future cash flow; the release says the programme does not oblige any purchase. Investors should watch the earnings call at 9:00 a.m. ET on Thursday, October 22, 2026, the Fed decision on Wednesday, October 28 and fourth-quarter awards.

Where Things Stand

The answer is that a book-to-bill of about 1.22 shows Medpace (NASDAQ:MEDP) signing more work than it delivered, with awards up 10.6% and backlog up 5.6% to USD 3.17 billion. Those orders sit alongside a 24.0% EBITDA margin and a new USD 1.0 billion buyback that runs to the end of 2028. The next catalysts are the call on October 22, the Fed decision on October 28 and fourth-quarter awards. Backlog can be cancelled, and this is not investment advice.